Abstracts tagged "rheumatoid arthritis (RA) and therapeutic targeting"

Abstract Number: 52 • 2018 ACR/ARHP Annual Meeting
Interferon-Alpha Protects Against Pain and Joint Damages in Experimental Arthritis and Is Associated with Expansion of Highly Suppressive Regulatory T Lymphocytes in Protected Mice and in Tocilizumab-Treated Rheumatoid Arthritis Patients
Matthieu Ribon¹, Roxane Hervé², Delphine Lemeiter², Katarzyna Matyja¹, François Santinon¹, Darragh Duffy³, Ken Tsumiyama⁴, Shunichi Shiozawa⁵, Marie-Christophe Boissier⁶, Natacha Bessis² and Patrice Decker¹, ¹Inserm UMR 1125, Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ²Li2P, University of Paris 13, Sorbonne Paris Cité, Bobigny, France, ³Institut Pasteur, Paris, Paris, France, ⁴Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Institute for Rheumatic Diseases, Nagahama, Japan, ⁶Rheumatology Department, AP-HP, Avicenne Hospital, Bobigny, France
Background/Purpose: Type I interferons (IFN-I) can be both anti- and pro-inflammatory. Among them, IFN-α inhibits normal Th17 differentiation, whereas it is pathogenic in lupus. The…
Abstract Number: 2491 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study
B Haraoui¹, Janet E. Pope², Isabelle Fortin³, Emmanouil Rampakakis⁴, John S. Sampalis^5,6, Francoise Romeyer⁷, Joseph Atallah⁷ and Louis Bessette⁸, ¹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ³Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, ⁴JSS Medical Research, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶JSS Medical Research, St-Laurent, QC, Canada, ⁷Bristol-Myers Squibb, Montreal, QC, Canada, ⁸Centre d'Osteoporose et de Rhumatologie de Quebec, Quebec, QC, Canada
Background/Purpose: The efficacy and safety of subcutaneous (SC) abatacept in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. However,…
Abstract Number: 59 • 2016 ACR/ARHP Annual Meeting
Novel Agents for Blocking the Interaction of Immune Complexes with the Activatory FcγRIIIa Receptor
James Robinson¹, Euan Baxter¹, Darren Tomlinson², Richard Foster³, Robin Owen⁴, Stephanie Win¹, Joanne Nettleship⁵, Christian Tiede², Jayakanth Kankanala², Raymond Owens⁵, Colin Fishwick³, Michael McPherson² and Ann Morgan⁶, ¹NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ²Astbury Centre, School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom, ³School of Chemistry, University of Leeds, Leeds, United Kingdom, ⁴Harwell Science and Innovation Campus, Diamond Light Source, Didcot, United Kingdom, ⁵Research Complex at Harwell, Oxford Protein Production Facility - UK, Oxford, United Kingdom, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain
Background/Purpose: Protein-protein interactions are essential for the control of cellular functions and critical for regulation of the immune system. One example is the binding of…
Abstract Number: 589 • 2016 ACR/ARHP Annual Meeting
Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon², Carlos Perez-Sanchez¹, Yolanda Jiménez-Gómez¹, Maria Carmen Abalos-Aguilera², Ivan Arias de la Rosa¹, Pedro Segui¹, Pilar Font-Ugalde¹, Maria Ángeles Aguirre Zamorano¹, Jerusalem Calvo-Gutierrez¹, Rafaela Ortega-Castro¹, M. Carmen Castro-Villegas³, Rocio Gonzalez-Conejero⁴, Constantino Martinez⁴, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras² and Nuria Barbarroja¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴Regional Centre for Blood Donation, University of Murcia, Murcia, Spain
Background/Purpose: Neutrophil extracellular traps (NETs) have recently been implicated in vascular damage and atherothrombosis. Extruded DNA fibers containing multiple proinflammatory and thrombotic molecules induce the…
Abstract Number: 2701 • 2015 ACR/ARHP Annual Meeting
An Expansion of Rare Lineage Intestinal Microbes Characterize Rheumatoid Arthritis
Jun Chen¹, John M. Davis III², Eric L. Matteson³ and Veena Taneja⁴, ¹Health Sciences Research, Mayo Clinic, Rochesert, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Immunology, Mayo Clinic, Rochester, MN
Background/Purpose: The adaptive immune response in Rheumatoid arthritis (RA) is influenced by an interaction between host genetics and environment, particularly the host microbiome. To define…
Abstract Number: 2364 • 2014 ACR/ARHP Annual Meeting
PET-CT Imaging of Joints: A Quantitative Tool for Developing Novel Anti-Inflammatory Drugs
Siba Raychaudhuri¹, Anupam Mitra², Smriti K. Raychaudhuri³ and Abhijit Chaudhari⁴, ¹Med/Rheumatology, Univ California Davis/VA Sac, Davis, CA, ²Dermatology, VA Sacramento Medical Center, Mather, CA, ³Rheumatology, VA Sacramento Medical Center, Mather, CA, ⁴Radiology, UC Davis School of Medicine, Sacramento, CA
Background/Purpose: Mouse collagen induced arthritis (CIA) is the most commonly used preclinical model to screen new drug candidates for inflammatory arthritis. The conventional read out…
Abstract Number: 1386 • 2014 ACR/ARHP Annual Meeting
Disease Flares during 10 Year Follow-up in Patients with Rheumatoid Arthritis Are Associated with Joint Damage Progression and Disability
I.M. Markusse¹, L. Dirven², Y.P. Goekoop-Ruiterman³, P.a. van der Lubbe⁴, A.J. Peeters⁵, P.J.S.M. Kerstens⁶, W.F. Lems^7,8, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁸Rheumatology, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: Disease flares frequently occur in patients with rheumatoid arthritis (RA). It has been suggested that these may spontaneously remit, in which case targeted treatment…
Abstract Number: 2745 • 2013 ACR/ARHP Annual Meeting
Reshaping Inflammatory Macrophage Development and Functions by a Monosaccharide Analogue In Rheumatoid Arthritis
Jun Li¹, Hui-Chen Hsu^2,3, PingAr Yang¹, Qi Wu¹, Bao Luo¹, Amber L Rowse⁴, David M. Spalding⁵, James A Mobley⁶, S. Louis Bridges Jr.⁷ and John D. Mountz^3,8, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Birmingham VA Medical Center, Birmingham, AL, ⁴Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Division of Clinical Immunology & Rheumatology, Birmingham, AL, ⁶University of Alabama at Birmingham, Comprehensive Cancer Center Mass Spectrometry/Proteomics Facility, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Inflammatory macrophages (MΦs) play key roles in pathogenesis of rheumatoid arthritis (RA). Fucosylation, comprising the transfer of a fucose (6-Deoxy-L-galactose) to proteins, is regulated…
Abstract Number: 1026 • 2013 ACR/ARHP Annual Meeting
Impact Of Basing Rheumatoid Arthritis Disease Activity Measurement and Treatment Recommendations On Patient Instead Of Physician Joint Assessments
Yomei Shaw¹, Daisy Bang², Heather Eng³, Stephen R. Wisniewski⁴, Mark S. Roberts¹ and Marc C. Levesque⁵, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, ³Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁴Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Current guidelines recommend treatment for rheumatoid arthritis (RA) be informed by a measure of disease activity such as the Disease Activity Score-28 (DAS28-CRP), which…
Abstract Number: 1027 • 2013 ACR/ARHP Annual Meeting
Factors Associated With Decisions To Adjust Therapy For Rheumatoid Arthritis Patients In Moderate To High Disease Activity
Yomei Shaw¹, Chung-Chou H. Chang^2,3, Heather Eng⁴, Ilinca D. Metes⁵, Stephen R. Wisniewski⁶, Mark S. Roberts¹ and Marc C. Levesque⁷, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁵Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The American College of Rheumatology (ACR) recommends treating rheumatoid arthritis (RA) to the target of low disease activity or remission with traditional and biologic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].